Related Experiment Videos
Vaccine therapy for cancer
D C Linehan1, P S Goedegebuure, T J Eberlein
1Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
Annals of Surgical Oncology
|March 1, 1996
Summary
Despite evidence of anti-cancer immune responses, cancer vaccines have shown limited success. New strategies targeting tumor-associated antigens (TAAs) and their epitopes offer cautious optimism for effective cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Tumor-specific cytotoxic T-lymphocytes (CTLs) indicate an existing cell-mediated immune response to cancer.
- Despite this, active specific immunotherapy using cancer vaccines has yielded limited clinical success.
Purpose of the Study:
- To review the immunobiology of cell-mediated anti-cancer immunity.
- To discuss recent advances in identifying tumor-associated antigens (TAAs) recognized by CTLs.
- To examine the implications of TAA discovery for developing novel anticancer vaccines.
Main Methods:
- Review of major histocompatibility complex (MHC)-restricted T-cell interactions with tumor cells.
- Analysis of identified TAAs and antigenic peptides in melanoma, ovarian, and breast cancers.
- Evaluation of current cancer vaccine trials and strategies for improving therapeutic efficacy.
Main Results:
- Identification of several MHC-restricted antigenic peptides recognized by CTLs in various cancers.
- Advances in understanding TAA recognition by tumor-specific CTLs.
- Progress in developing genetically engineered tumor cell vaccines.
Conclusions:
- Recent TAA and peptide discoveries are driving new anticancer vaccine development strategies.
- Improved understanding of cancer immunobiology fuels cautious optimism for effective immunotherapies.
- Continued research into TAAs and CTL responses is crucial for advancing cancer vaccines.